From May 10 to 11, 2024, the 2024 Taihu Bay Future Healthcare Conference was held in Wuxi, Jiangsu Province. As one of the partners of the Jade Ribbon Liver Cancer Early Screening and Diagnosis Program (referred to as the Jade Ribbon Program), Dunwill Medical was invited to participate in this conference. The Green Ribbon Program, led by Zhongshan Hospital affiliated with Fudan University, will fully utilize Shanghai's advantages in biomedicine, promote the standardization of liver cancer diagnosis and treatment, explore the "Shanghai model" for early diagnosis of liver cancer, and help achieve important overall cancer prevention and treatment goals in China.

During this conference, Dunwill Medical brought its product miRNA7™—— the first liver cancer molecular detection product approved by NPMA in China made an appearance at the exhibition and received widespread attention. As an innovative method for early diagnosis of liver cancer, miRNA7™ can effectively improve the efficiency of early diagnosis of liver cancer, and the sensitivity of very early liver cancer is about 30% higher than traditional biomarkers. It has been included in multiple authoritative guidelines and consensus such as the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition). MiRNA7™ will assist the "Jade Ribbon Plan" in raising public awareness of early detection and diagnosis of liver cancer, establishing a stratified screening model for different risk factors of liver cancer, improving the sensitivity and specificity of early detection technology for liver cancer, and helping to achieve China's important overall goal  of cancer prevention and control - to increase the 5-year survival rate of liver cancer patients in China by more than 15% by 2030.

China is a major country in liver cancer, with nearly 50% of new cases and deaths worldwide each year, and a five-year survival rate of only 12%. In the context of existing diseases, early detection and diagnosis as well as timely intervention in various stages of early liver cancer are the keys to improving the quality of liver cancer prevention and treatment in China. This is also the profound practical significance contained in the "Jade Ribbon Program" that has been launched. The specific action plan of this project is expected to cover 50 million people for early detection and disease education for liver cancer within 2 years, and provide free testing for 50,000 high-risk population for liver cancer.

Through the launch of the "Jade Ribbon Program", we look forward to exploring practical and feasible advanced models for early diagnosis of liver cancer that are in line with China's national conditions and further promoting successful experiences nationwide, effectively promoting early diagnosis and treatment of liver cancer in China, improving the five-year survival rate of Chinese liver cancer patients, and jointly building a national health defense line.